Literature DB >> 10569655

Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation.

T Z Naqvi1, P K Shah, P A Ivey, M D Molloy, A M Thomas, S Panicker, A Ahmed, B Cercek, S Kaul.   

Abstract

Plasma total and low-density lipoprotein (LDL) cholesterol are established risk factors for atherosclerotic vascular disease and may also contribute to a prothrombotic risk via enhanced platelet reactivity. This study examines whether high-density lipoprotein (HDL) cholesterol, which is inversely correlated with coronary artery disease, is associated with a reduced thrombogenic potential. Platelet thrombus formation was evaluated by exposing porcine aortic media placed in Badimon perfusion chambers to flowing nonanticoagulated venous blood for 5 minutes at a shear rate of 1,000 s(-1). Forty-five subjects, 23 normal (LDL 104 +/- 31, HDL 50 +/- 15 mg/dl) and 22 hypercholesterolemic (LDL 181 +/- 45, HDL 41 +/- 10 mg/dl) patients without coronary artery disease were studied. Platelet aggregation and CD62 antigen expression, and assay for circulating prothrombotic factors were also performed. In univariate analysis platelet thrombus formation correlated with weight (r = 0.33, p = 0.03), diastolic blood pressure (r = 0.39, p = 0.01), HDL cholesterol (r = -0.45, p = 0.003), total/HDL cholesterol (r = 0.43, p = 0.004) and LDL/HDL (r = 0.38, p = 0.01) ratios, and platelet CD62 expression (r = 0.41, p = 0.02). In multiple regression analysis only HDL cholesterol showed significant correlation with platelet thrombus formation (p = 0.03). Platelet aggregation and circulating prothrombotic factors did not correlate with platelet thrombus formation. A comparison between normal and hypercholesterolemic subjects revealed enhanced thrombus area (0.026 +/- 0.20 vs 0.045 +/- 0.039 mm2/mm; p = 0.04), resting CD62 expression (6 +/- 7% vs 15 +/- 10% positive platelets, p = 0.02), and platelet aggregation (16.7 +/- 5.2 vs 21.7 +/- 6.7 ohms, p = 0.04) in hypercholesterolemic subjects. Our results demonstrate that HDL cholesterol is a significant independent predictor of ex vivo platelet thrombus formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569655     DOI: 10.1016/s0002-9149(99)00489-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 3.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 4.  Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.

Authors:  John A Farmer; Joshua Liao
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

5.  Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats.

Authors:  A A Seif
Journal:  Ir J Med Sci       Date:  2014-03-15       Impact factor: 1.568

Review 6.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

7.  Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport.

Authors:  Gabriella A Papale; Kay Nicholson; Paul J Hanson; Mitja Pavlovic; Victor A Drover; Daisy Sahoo
Journal:  Arch Biochem Biophys       Date:  2010-02-26       Impact factor: 4.013

8.  Emerging HDL-based therapies for atherothrombotic vascular disease.

Authors:  Prediman K Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02

Review 9.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Authors:  Kaylin M McMahon; Linda Foit; Nicholas L Angeloni; Francis J Giles; Leo I Gordon; C Shad Thaxton
Journal:  Cancer Treat Res       Date:  2015

10.  Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI.

Authors:  Manojkumar Valiyaveettil; Niladri Kar; Mohammad Z Ashraf; Tatiana V Byzova; Maria Febbraio; Eugene A Podrez
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.